VAXART INC. - COMMON STOCK

Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results

08 11 2022 16:01:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8

20 10 2022 08:30:00 提供 Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Europe 2022 on October 13

10 10 2022 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference

07 9 2022 08:30:01 提供 Nasdaq GlobeNewswire

Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate

01 9 2022 06:30:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial

31 8 2022 16:30:00 提供 Nasdaq GlobeNewswire

Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer

31 8 2022 08:30:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors

25 8 2022 16:05:00 提供 Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results

08 8 2022 16:01:01 提供 Nasdaq GlobeNewswire

Vaxart Appoints W. Mark Watson to its Board of Directors

08 8 2022 08:00:01 提供 Nasdaq GlobeNewswire

Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4

05 8 2022 08:00:00 提供 Nasdaq GlobeNewswire

Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8

28 7 2022 16:05:00 提供 Nasdaq GlobeNewswire

Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET

27 7 2022 08:00:01 提供 Nasdaq GlobeNewswire

Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive

20 7 2022 08:30:00 提供 Nasdaq GlobeNewswire

Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022

14 7 2022 08:00:01 提供 Nasdaq GlobeNewswire

Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET

01 7 2022 09:00:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model

30 6 2022 08:00:01 提供 Nasdaq GlobeNewswire

Vaxart to Host Investor Q&A Webcast

16 6 2022 16:05:00 提供 Nasdaq GlobeNewswire

Vaxart Announces Adjournment of Annual Meeting of Stockholders

08 6 2022 09:05:00 提供 Nasdaq GlobeNewswire

New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron

03 6 2022 08:00:00 提供 Nasdaq GlobeNewswire